In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Acquisition Of Agis Will Extend Its Generic Rx Product Line

This article was originally published in The Pink Sheet Daily

Executive Summary

The merger represents the culmination of a 15-month search by Perrigo to implement the OTC company's strategy of entering the faster growing Rx generic drugs market. Perrigo expects the $818 mil. acquisition of Agis to close during the second quarter of 2005.

You may also be interested in...



Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles

A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles

Sepracor Lunesta Ads Are Top At Brand Recognition, IAG Research Finds

Sepracor's television ads for its sleep aid Lunesta create brand recognition better than other new prescription drug direct-to-consumer ads, according to an analysis performed by IAG Research

Topics

UsernamePublicRestriction

Register

PS058132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel